Skip to main content
TipRanks
Go Ultimate75% OFF

Mizuho Medy Co., Ltd. (4595) AI Stock Analysis

0 Followers
JP:4595

Mizuho Medy Co., Ltd.

(TSE/TYO:4595)

Select Model
Rating:73Outperform
Price Target:JPY 1,864.00â–²(10.56% Upside)
Action:upgraded
Date:11/07/26

The score is driven primarily by solid fundamentals: a debt-free balance sheet, high equity ratio and above-average margins, tempered by a meaningful revenue contraction from pandemic-era highs, margin compression and weaker cash conversion. Valuation is a clear positive, with a single-digit P/E and a near 6% dividend yield backed by positive free cash flow. The main drag is technical weakness, as the stock trades below all key moving averages with negative MACD and subdued RSI/stochastic readings, suggesting limited near-term momentum despite the attractive fundamental and valuation profile.

Positive Factors
Recurring consumables modelMizuho Medy’s reagent and test-kit model creates repeat purchasing as laboratories conduct ongoing clinical testing. This recurring consumables exposure can support durable demand, improve customer retention, and provide a foundation for revenue resilience as testing volumes continue.
Negative Factors
Normalized growth and marginsRecent growth is modest compared with the company’s earlier peak performance, while lower margins indicate reduced earnings leverage from revenue. If this normalization persists, Mizuho Medy may have less capacity to compound profits and could face a slower improvement trajectory.

Mizuho Medy Co., Ltd. (4595) vs. iShares MSCI Japan ETF (EWJ)

-5%0%5%10%15%20%25%30%JP:4595+9.11%EWJ+6.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 32.12B
Dividend Yield
5.93%
Average Volume (3M)
77.42K
Price to Earnings (P/E)
9.4
Beta (1Y)
0.40
Revenue Growth
16.55%
EPS Growth
21.38%
Country
Japan
Employees
193
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Mizuho Medy Co., Ltd. Business Overview & Revenue Model

Company Description

Established in 1977 and headquartered in Tosu, Japan, Mizuho Medy Co.,Ltd. specializes in the research, development, production, and distribution of in-vitro diagnostic solutions, complemented by scientific and technical information services. While i...

How the Company Makes Money

The company primarily makes money by selling IVD products, with revenue largely driven by diagnostic reagents and test kits that are consumed repeatedly as tests are performed. A typical revenue model in this business consists of (1) recurring consum...

Mizuho Medy Co., Ltd. Financial Statement Overview

Summary

Mizuho Medy combines a pristine balance sheet (zero debt, ~84% equity ratio, equity grown from ¥3.8B in 2020 to ¥18.7B) with still-strong profitability (30.4% net margin, 43.6% EBITDA margin) and modest 4.9% revenue growth. Offsetting this, revenue has fallen sharply from the 2022 peak of ¥17.6B to ¥11.3B, gross margins compressed from 80.2% to 69.1%, and cash conversion has weakened (operating cash flow down to ¥2.0B from ¥3.3B, OCF/net income of 0.74). Overall a financially sound business normalizing after pandemic-driven demand.

Income Statement

72Positive

Balance Sheet

88Very Positive

Cash Flow

65Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue10.82B11.26B11.43B10.99B17.58B12.89B
Gross Profit7.40B7.78B8.04B8.03B14.05B9.61B
EBITDA4.44B4.91B5.10B5.40B11.26B6.87B
Net Income3.23B3.42B3.77B3.77B7.84B4.82B
Balance Sheet
Total Assets20.99B22.38B20.73B18.95B19.10B12.19B
Cash, Cash Equivalents and Short-Term Investments13.06B10.82B11.25B10.13B8.70B4.33B
Total Debt000000
Total Liabilities2.43B3.69B3.37B3.27B4.82B4.16B
Stockholders Equity18.55B18.68B17.35B15.68B14.28B8.03B
Cash Flow
Free Cash Flow01.70B3.05B3.73B5.99B5.44B
Operating Cash Flow01.96B3.35B3.99B6.17B5.60B
Investing Cash Flow0-7.28B-307.00M-270.45M-1.55B-159.74M
Financing Cash Flow0-2.08B-2.09B-2.38B-1.57B-1.16B

Mizuho Medy Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price1686.00

Price Trends

50DMA1715.44Negative
100DMA1700.34Negative
200DMA1715.22Negative

Market Momentum

MACD-3.64Positive
RSI43.82Neutral
STOCH22.56Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4595, the sentiment is Negative. The current price of 1686.00 is below the 20-day moving average (MA) of 1708.35, below the 50-day MA of 1715.44, and below the 200-day MA of 1715.22, indicating a bearish trend. The MACD of -3.64 indicates Positive momentum. The RSI at 43.82 is Neutral, neither overbought nor oversold. The STOCH value of 22.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4595.

Mizuho Medy Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4595 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4595JP:459573OutperformJPY 32.39B9.41―5.93%16.55%21.38%
JP:4534JP:453473OutperformJPY 114.51B11.067.68%2.45%15.85%60.55%
JP:4554JP:455469NeutralJPY 46.15B15.585.56%3.03%20.72%-10.35%
JP:4886JP:488669NeutralJPY 56.74B11.31―3.14%―9.04%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4539JP:453946NeutralJPY 5.70B-11.69―3.25%0.31%-194.72%
JP:4892JP:489242NeutralJPY 5.08B-6.33――214.65%22.18%

* Healthcare Sector Average

Performance Comparison

0%20%40%JP:4595JP:4554JP:4534JP:4539JP:4886JP:4892Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4595 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4595Mizuho Medy Co., Ltd.1686.00158.6910.39%
JP:4554Fuji Pharma Co., Ltd.1717.00-0.78-0.05%
JP:4534Mochida Pharmaceutical Co., Ltd.3365.0084.752.58%
JP:4539Nippon Chemiphar Co., Ltd.1540.0059.184.00%
JP:4886ASKA Pharmaceutical Holdings Co., Ltd.2072.0067.403.36%
JP:4892Cyfuse Biomedical K.K.487.00-83.00-14.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026